Name: Section A Group 6

Roll No:
PGP202A009 Ashish Singh
PGP202A022 Harikrishnan V
PGP202A039 Prajwal M
PGP202A055 Shubhomoy Daripa
PGP202A070 Shruti Vishwakarma
 BALANCE SHEET (All amounts in Indian Rupees millions, except share data and where otherwi

Particulars
ASSETS:
Non Current Assets

(a) Property, plant and equipment

(b) Capital work-in-progress

(c) Goodwill

(d) Other intangible assets

(e) Intangible assets under development

(f) Financial assets:

(i) Other investments

(ii) Trade receivables

(iii) Loans

(iv) Other financial assets

(g) Deferred tax assets (net)

(h) Tax assets (net)

(i) Other non-current assets

Total Non Current Assets

Current Assets:

(a ) Inventories

(b) Financial assets:

(i) Investments

(ii) Trade receivables

(iii) Derivative instruments

(iv) Cash and cash equivalents

(v) Other financial assets

(c) Other current assets

Tota Current Assets

Total Assets

Equity:
(a) Equity share capital

(b) Other Equity

Total Equity

Liabilities
Financial Liabilities
(a) Non Current Liabilities:

(i) Borrowings

(b) Provisions

(c) Deferred tax liabilities (net)

(d) Other non-current liabilities

Total Non Current Liabilities

Current Liabilities:
(a) Financial liabilities:

(i) Borrowings

(a) Total outstanding dues of micro and small enterprises

(b) Total outstanding dues of creditors other than micro and small enterprises

(c) Derivative instruments

(b) Other financial liabilities

(c) Provisions

(d) Other current liabilities

Total Current Liabilities

Total Liabilities and Equity

The accompanying notes are an integral part of the financial statements.

As per our report of even date attached for S.R. Batliboi & Associates LLP for and on behalf of the Board of Directors of Dr. Red
Chartered Accountants
ICAI Firm registration number: 101049W/E300004
per S Balasubrahmanyam

Partner
Membership No.: 53315
Place : Hyderabad
Date : 17 May 2019
d where otherwise stated)

As on 31 March 2020 As on 31 March 2019 As on 31 March 2018

37,698 39504.00 39790.00

3,841 4001.00 6750.00
323 323.00 323.00
6,318 7000.00 7060.00
277

33,671 18,191 19,537

1,737 113 169.00
12 332 1,991
474 447 437
6,129 931
3,073 3,106 3,518
138 126.00 112
93,691 73143.00 80618.00

21,904 20,156 18,568

21,184 21,144 16,828

46,387 37,177 42,038
783 335 17
392 1,132 1,207
1,888 692 509
8,529 8,696 11,218
101,067 89332.00 90385.00
194758.00 162475.00 171003.00
 831 830 830
151,088 126,011 117,248
151,919 126841.00 118078.00

193 3,454 4,880

545 547 533
NA 555
296 285 313
1,034 4841.00 5726.00

10,436 5,463 21,008

55 77 93
10,629 10,239 10,517
1,524 45 85
13,928 10,160 11,386
2,073 1,847 1,734
3,160 2,962 2,376
41,805 30793.00 47199.00
194,758 162475.00 171003.00
151,919

ectors of Dr. Reddy’s Laboratories Limited

K Satish Reddy Chairman

G V Prasad Co-Chairman & Chief Executive Offi cer
Erez Israeli Chief Executive Offi cer
Saumen Chakraborty Chief Financial Offi cer
Sandeep Poddar Company Secretary
 STATEMENT OF PROFIT AND LOSS (All amounts in Indian Rupees millions, except

Particulars
Income
Sales
Service income and License fees
Other operating income
Total revenue from operations
Other income
Total income

Expenses
Cost of materials consumed
Purchase of stock-in-trade
Changes in inventories of finished goods, work-in-progress and stock-in-trade
Employee benefits expense
Depreciation and amortisation expense
Finance costs
Selling and other expenses
Total expenses

Profit before tax

Tax expense
Current tax
Deferred tax
Profit for the year

Other comprehensive income (OCI)

Items that will not be reclassified subsequently to profit or loss
Income tax on items that will not be reclassified subsequently to profit or loss

Items that will be reclassified subsequently to profit or loss

Income tax on items that will be reclassified subsequently to profit or loss
Total other comprehensive income/(loss) for the year, net of tax

Total comprehensive income for the year

Earnings per share:

Basic earnings per share of ` 5/- each
Diluted earnings per share of ` 5/- each

As per our report of even date attached for S.R. Batliboi & Associates LLP for and on behalf of the Board of Directors of Dr. Red
Chartered Accountants
ICAI Firm registration number: 101049W/E300004
per S Balasubrahmanyam

Partner
Membership No.: 53315
Place : Hyderabad
Date : 17 May 2019
SS (All amounts in Indian Rupees millions, except share data and where otherwise stated)

As on 31 March 2020 As on 31 March 2019 As on 31 March 2018

109,925 104,667 92,468

8,105 1,062 558
474 526 567
118,504 106,255 93,593
7,432 2,384 2,040
125,936 108,639 95,633

25,565 21,032 20,110

11,172 8,686 6,716
-999 660 (516)
20,302 19,319 18,430
7,892 7,806 7,741
478 568 628
33,768 33,561 35,554
98,178 91,632 88,663

27,758 17,007 6,970

4,839 2,818 1,381

(6458) 1,416 (80)
29,377 12,773 5,669

88 (1) 43
(33) 3 (16)
55
(750) 209 (133)
259 (73) 46
(491) 136
 (436) 138 (60)

28,941 12,911 5,609

177.23 76.98 34.19

176.88 76.85 34.12

on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited

K Satish Reddy Chairman

G V Prasad Co-Chairman & Chief Executive Offi cer
Erez Israeli Chief Executive Offi cer
Saumen Chakraborty Chief Financial Offi cer
Sandeep Poddar Company Secretary
 STATEMENT OF CASH FLOWS (All amounts in Indian Rupees millions, except s

Particulars

Cash flow/(used in) operating activities

Profit before tax
Adjustments:
Depreciation and amortisation expense
Impairment loss on other intangible assets
Equity settled share-based payment expense
Fair value gain on financial instruments at fair value through profit or loss
Foreign exchange loss/(gain), net
(Profit)/loss on sale/disposal of property , plant and equipment and other intangible assets, net
Interest income
Finance costs
Profit on sale of mutual funds, net
Refund liability
Inventory write-downs
Allowances for credit losses, net
Allowances for doubtful advances, net
Loss on sale of non-current investments
Dividend from subsidiary, joint ventures and other entities
Provision/(reversal of provision) relating to non-current investments
Changes in operating assets and liabilities:
Trade receivables
Inventories
Trade payables
Other assets and other liabilities, net
Cash generated from operations
Income taxes paid, net from operations

Net cash from operating activities

Cash flows from/(used in) investing activities

Proceeds from sale of property, plant and equipment
Expenditures on property, plant and equipment
Expenditures on other intangible assets
Purchase of investments
Proceeds from sale of investments
Divident income received
Loans and advances repaid by subsidiaries
Interest income received

Net cash used in investing activities

Cash flows from/(used in) financing activities

Proceeds from issuance of equity shares

Proceeds from/(repayment of) short-term loans and borrowings, net (Refer note 2.8 (d))
Proceeds from/(repayment of) long-term loans and borrowings, net (Refer note 2.8 (d))
Payment of principal portion of lease liabilities (Refer note 2.9 (d))
Dividends paid (including corporate
Purchases of treasury shares
Interest paid

Net cash used in financing activities

Net increase/(decrease) in cash and cash equivalents

Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents at the beginning of the year (Refer note 2.4 E)
Cash and cash equivalents at the end of the year (Refer note 2.4 E)
*Rounded off to millions.

As per our report of even date attached for S.R. Batliboi & Associates LLP for and on behalf of the Board of Directors of Dr. Red
Chartered Accountants
ICAI Firm registration number: 101049W/E300004
per S Balasubrahmanyam

Partner
Membership No.: 53315
Place : Hyderabad
Date : 17 May 2019
dian Rupees millions, except share data and where otherwise stated)

As on 31 March 2020 As on 31 March 2019 As on 31 March 2018

27,758 17,007 6,970

7,892 7,806 7,741

NA 24 53
521 389 454
(821) (669) (33)
(229) 2,455 (665)
135 (400) 55
(856) (812) (649)
478 568 628
No data for 2020 (448) (779)
No data for 2020 1,090 1,105
No data for 2020 2,085 1,965
93 212 (12)
2 (351) (36)
No data for 2020 - 341
(397)
NA 359 (525)

(10927) 4,547 3,361

(1748) (1588) (2,436)
368 (201) 2,738
892 663
23,161 30,009 17126
(4769) (2388) (3150)

18,392 27,621 15,386

58 879 124
(4262) (5,775) (7,689)
(476) (753) (293)
 (122726) (77,267) (60,620)
109,186 74,786 56,278
397 NA NA
343 1,800 63
588 821 338

(16892) (5,509) (11,799)

4 1
4,630 (17,049) 1654
(1805) NA (1)
(155) NA NA
(3914) (4,002) (3,992)
(474) (535) -
(527) (645) (706)

(2241) (22,231) (3,044)

(741) (119) 543

NA 44 (3)
1,132 1,207 667
391 1,132 1,207

Board of Directors of Dr. Reddy’s Laboratories Limited

K Satish Reddy Chairman

G V Prasad Co-Chairman & Chief Executive Offi cer
Erez Israeli Chief Executive Offi cer
Saumen Chakraborty Chief Financial Offi cer
Sandeep Poddar Company Secretary
Typical Name of Ratio
Short-Term Liqudty Ratios
Current Ratio
Quick Ratio
Average Recievable Turnover
Average Collection Period
Creditor Turnover Ratio(CTR)
CPP
Inventory Turnover
Long-term solvency ratios
Total-debt-to-total-assets
Total-debt-to-total-equity
Interest coverage (2)
Profitability Ratios
Return on common stockholders'
equity (ROE)
Gross profit rate or percentage
Return on sales or profit margin
Total asset turnover
EBIT to sales
Return on assets (ROA)
Earnings per share, basic (EPS)
Market price and dividend ratios
Price-earnings (P-E)
Book value per common share
Market-to-book
Dividend-yield
Dividend-payout
Numerator
Current Assets
Current Assets-Inventories
Credit Sales
365
Cost of Sales
365
Cost of Sales
Total liabilities
Total liabilities(
Earnings before interest
expense and taxes
Captial Employed
Net Income minus Preffered Dividend
Gross profit or gross margin
Net income
Sales
Earnings before interest
Earnings before interest
Net income minus preferred
dividends, if any
Market price of common share
Common stockholders' equity
Market price of common share
Dividends per common share
Dividends per common share
A Working Capital
B Retained Earnings
C EBIT
D Market Value of Equity
E Sales

Zscore 3.28055969783864

ROE Net Profit

Denominator 2020 2019

Current Liabilities 2.42 2.90

Current Liabilities 1.89362516 2.24648459065372
Average accouts recievables 2.46247195 2.84942343791901
Account Recievable Turnover 148.225039 128.096089595784

Trade Payables 5.33714286 4.74978495651343

CTR 68.388651 76.8455842404974

Average Inventory at Cost 1.70 0.0000000000 1.5

Total assets 0.21996016 0.219319895368518

Stockholders' equity 0.2819858 0.280934398183553
Interest expense 59 31

152953 Assets Side

152953 Equity Sides

Average Common Stockholders Equity 21% 10%

Sales 0.52710457 0.532285539504023

Sales 0.24789881 0.120210813608771
Average total assets 0.66345494 0.637253432010507
Sales 0.2382704 0.1654040
Average total assets 0.1580817 0.1054043
Average common 177.227838 76.9856505690694
shares outstanding

Earnings per share 17.6086897

Number of common shares outstanding 914.811265
Book value per common share 4.73321675
Market price of common share 0.6%
Earnings per share 14%
Total Assets 0.30428532 0.360295430066164
Total Assets 0.77577301 0.775571626404062
Total Assets 0.1449799 0.1081705
Total Liabilities 1.23738901 1.50585051087195
Total Assets 0.60846794 0.653977535005386
z
1.2A+1.4B+3.3C+0.6D+1.0E

3.43260524420589

Equity 151919 126841

 Tota Current Assets 101067 89332
Total Assets 194758 162475 171003

Total Equity 151919 126841 118078

Total Non Current Liabilities 1034 4841

Total Current Liabilities 41805 30793

Total Liabilities and Equity 194758 162475

(a ) Inventories 21,904 20,156

Total revenue from operations 118504 106,255

non Curren (ii) Trade receivables 1,737 113 169.00

Current (ii) Trade receivables 46,387 37,177 42,038

Average Accounts Recievable 48,124 37,290

Employee benefits expense 20,302 19,319 18,430

Cost of materials consumed 25,565 21,032 20,110
Purchase of stock-in-trade 11,172 8,686 6,716
Changes in inventories of finished (999) 660 (516)
cost of sales 56,040 49697

(a) Total outsta 55 77 93

(b) Total outsta 10,629 10,239 10,517
Trade Payables 10684 10316 10610
Average Trade Payables 10500 10463

Profit before tax 27,758 17,007 6,970

Finance costs 478 568 628

Profit for the year 29,377 12,773

Total revenue from operations 118,504 106,255 93,593

Weighted average number of equ165,758,384 165,914,036

 (b) Other Equity 151,088 126,011

Market Price
3120.75 2794.8

B+3.3C+0.6D+1.0E
Particulars As on 31 March 2020
ASSETS: CY
Non Current Assets
(a) Property, plant and equipment 37,698
(b) Capital work-in-progress 3,841
(c) Goodwill 323
(d) Other intangible assets 6,318
(e) Intangible assets under development 277
(f) Financial assets:
(i) Other investments 33,671
(ii) Trade receivables 1,737
(iii) Loans 12
(iv) Other financial assets 474
(g) Deferred tax assets (net) 6,129
(h) Tax assets (net) 3,073
(i) Other non-current assets 138
Total Non Current Assets 93,691
Current Assets:
(a ) Inventories 21,904
(b) Financial assets:
(i) Investments 21,184
(ii) Trade receivables 46,387
(iii) Derivative instruments 783
(iv) Cash and cash equivalents 392
(v) Other financial assets 1,888
(c) Other current assets 8,529
Tota Current Assets 101,067
Total Assets 194758.00
Equity:
(a) Equity share capital 831
(b) Other Equity 151,088
Total Equity 151,919
Liabilities
Financial Liabilities
(a) Non Current Liabilities:
(i) Borrowings 193
(b) Provisions 545
(c) Deferred tax liabilities (net) NA
(d) Other non-current liabilities 296
 Total Non Current Liabilities 1,034

Current Liabilities:
(a) Financial liabilities:
(i) Borrowings 10,436
(a) Total outstanding due 55
(b) Total outstanding due 10,629
(c) Derivative instruments 1,524
(b) Other financial liabilities 13,928
(c) Provisions 2,073
(d) Other current liabilities 3,160
Total Current Liabilities 41,805
Total Liabilities and Equity 194,758
As on 31 March 2019 Absolute Variance Percentage Percentage of Asset
PY CY-PY Absolute Variance/PY% 2020 2019

39504.00 -1,806.00 -4.57% 19.36% 24.31%

4001.00 -160.00 -4.00% 1.97% 2.46%
323.00 0.00 0.00% 0.17% 0.20%
7000.00 -682.00 -9.74% 3.24% 4.31%
277.00 0.14% 0.00%

18,191 15,480.00 85.10% 17.29% 11.20%

113 1,624.00 1437.17% 0.89% 0.07%
332 -320.00 -96.39% 0.01% 0.20%
447 27.00 6.04% 0.24% 0.28%
6,129.00 3.15% 0.00%
3,106 -33.00 -1.06% 1.58% 1.91%
126.00 12.00 9.52% 0.07% 0.08%
73143.00 20,548.00 28.09% 48.11% 45.02%

20,156 1,748.00 8.67% 11.25% 12.41%

21,144 40.00 0.19% 10.88% 13.01%

37,177 9,210.00 24.77% 23.82% 22.88%
335 448.00 133.73% 0.40% 0.21%
1,132 -740.00 -65.37% 0.20% 0.70%
692 1,196.00 172.83% 0.97% 0.43%
8,696 -167.00 -1.92% 4.38% 5.35%
89332.00 11,735.00 13.14% 51.89% 54.98%
162475.00 32,283.00 19.87% 100.00% 100%

830 1.00 0.12% 0.43% 0.51%

126,011 25,077.00 19.90% 77.58% 77.56%
126841.00 25,078.00 19.77% 78.00% 78.07%

3,454 -3,261.00 -94.41% 0.10% 2.13%

547 -2.00 -0.37% 0.28% 0.34%
555 0.34%
285 11.00 3.86% 0.15% 0.18%
 4841.00 -3,807.00 -78.64% 0.53% 2.98%

5,463 4,973.00 91.03% 5.36% 3.36%

77 -22.00 -28.57% 0.03% 0.05%
10,239 390.00 3.81% 5.46% 6.30%
45 1,479.00 3286.67% 0.78% 0.03%
10,160 3,768.00 37.09% 7.15% 6.25%
1,847 226.00 12.24% 1.06% 1.14%
2,962 198.00 6.68% 1.62% 1.82%
30793.00 11,012.00 35.76% 21.47% 18.95%
162475.00 32,283.00 19.87% 100% 100%
Particulars As on 31 March 2020
Income
Sales 109,925
Service income and License fees 8,105
Other operating income 474
Total revenue from operations 118,504
Other income 7,432
Total income 125,936

Expenses
Cost of materials consumed 25,565
Purchase of stock-in-trade 11,172
Changes in inventories of finished goods, work-in-progr (999)
Employee benefits expense 20,302
Depreciation and amortisation expense 7,892
Finance costs 478
Selling and other expenses 33,768
Total expenses 98,178

Profit before tax 27,758

Tax expense
Current tax 4,839
Deferred tax (6458)
Profit for the year 29,377

Other comprehensive income (OCI)

Items that will not be reclassified subsequently to p 88
Income tax on items that will not be reclassified sub (33)
55
Items that will be reclassified subsequently to profit (750)
Income tax on items that will be reclassified subsequ 259
(491)

Total other comprehensive income/(loss) for the yea (436)

Total comprehensive income for the year 28,941

Earnings per share:

Basic earnings per share of ` 5/- each 177.23
Diluted earnings per share of ` 5/- each 176.88
As on 31 March 2019 Percentage of Total Absolute VPercentage
CY-PY Absolute Variance/PY%
104,667 87.29% 96.34% 5,258 5.02%
1,062 6.44% 0.98% 7,043 663.18%
526 0.38% 0.48% -52 -9.89%
106,255 94.10% 97.81% 12,249 11.53%
2,384 5.90% 2.19% 5,048 211.74%
108,639 100.00% 100.00% 17,297 15.92%

21,032 4,533 21.55%

8,686 2,486 28.62%
660 -1,659 -251.36%
19,319 983 5.09%
7,806 86 1.10%
568 -90 -15.85%
33,561 207 0.62%
91,632 6,546 7.14%

17,007 10,751 63.22%

2,818 2,021 71.72%

1,416 -7,874 -556.07%
12,773 16,604 129.99%

(1) 89 -8900.00%
3 -36 -1200.00%
55
209 -959 -458.85%
(73) 332 -454.79%
136 -627 -461.03%

138 -574 -415.94%

12,911 16,030 124.16%

76.98 100 130.23%

76.85 100 130.16%
Particulars For the year ended
31-Mar-20
For the year ended
31-Mar-19
For the year ended
31-Mar-18
Revenues 174,600 153,851 142,028
Cost of revenues 80,591 70,421 65,724
Gross profi t 94,009 83,430 76,304
Selling, general and administrative expenses 50,129 48,680 46,857
Research and development expenses 15,410 15,607 18,265
Impairment of non-current assets 16,767 210 53
Other income, net -4,290 -1,955 -788
Total operating expenses 78,016 62,542 64,387
Results from operating activities (A) 15,993 20,888 11,917
Finance income 2,461 2,280 2,897
Finance expense -983 -1,163 -817
Finance income, net (B) 1,478 1,117 2,080
Share of profi t of equity accounted investees, n 561 438 344
Profi t before tax [(A)+(B)+(C)] 18,032 22,443 14,341
Tax (expense)/benefi t, net 1,466 -3,648 -4,535
Profi t for the year 19,498 18,795 9,806
Earnings per share:
Basic earnings per share of ` 5/- each 117.63 113.28 59.13
Diluted earnings per share of ` 5/- each 117.4 113.09 59